

This information was up to date at the time of release to the Heads of Midwifery.

The editorial board does not accept liability for any errors or omissions following its subsequent publication.

Updating arrangements for the formulary should be decided upon and implemented at a local level.

Nystatin oral suspension (neonate)	
Legal status (GSL, P or POM on exemption list, or PGD)	<ul style="list-style-type: none"> ▪ POM - midwife may supply as medicine is on midwives exemptions list
Patient group	neonates
Clinical indication	Treatment of candidal infections of the oral cavity, oesophagus and intestinal tract.
Pharmacology (Onset and duration of action where appropriate)	<p>Nystatin is an antifungal antibiotic active against a wide range of yeasts and yeast-like fungi, including <i>Candida albicans</i>.</p> <p>To prevent re-infection and relapse ensure that mother's nipples and teats of feeding bottles are cleaned adequately and continue for 48 hours after cure.</p>
Pharmaceutical form, strength, route of administration	<p>Oral suspension.</p> <p>Ready mixed containing 100,000 units nystatin per ml.</p> <p>For oral administration.</p>
Dose, frequency and maximum number of doses or period of time for administration or supply	<p>1ml 4 times a day after feeds.</p> <p>Shake bottle well before use.</p> <p>Maximum of 1 bottle of 30ml.</p>
Contra-indications/exclusion criteria	<ul style="list-style-type: none"> ▪ there are two products - both contain sugar and one product also contains ethanol (Nystan[®] ready mixed) ▪ babies with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine ▪ known hypersensitivity to any component of the medicine
Cautions and action that will be taken if a caution applies	<ul style="list-style-type: none"> ▪ check for and document any allergies ▪ check and document past medical and drug history and current medication to ascertain potential for overdose ▪ if a caution applies consult with a doctor ▪ document consultation in maternity record
Drug interactions and action that will be taken if a patient is taking a medicine that may interact	<ul style="list-style-type: none"> ▪ none known ▪ if there is a clinically significant drug interaction, consult with a doctor before administration or supply ▪ document consultation in maternity record ▪ refer to current BNF for latest information on interactions

Nystatin oral suspension (neonate)

<p>Potential adverse reactions and side effects including actions to be taken if adverse drug reaction is suspected</p>	<ul style="list-style-type: none"> ▪ normally well tolerated but oral irritation or sensitisation, and nausea and diarrhoea with large doses reported ▪ rash, including urticaria and facial oedema has been reported rarely. Steven-Johnson Syndrome has been reported very rarely ▪ on labour Nil ▪ on the neonate Nil ▪ on breast feeding Nil ▪ if a serious adverse reaction is suspected please report to the MHRA Yellow Card Scheme. http://yellowcard.mhra.gov.uk/
<p>Overdose</p>	<ul style="list-style-type: none"> ▪ no systemic toxicity reported ▪ immediate assessment/treatment is essential - refer to medical staff ▪ manage in accordance with established treatment guidelines or see BNF overdose section ▪ for further advice contact National Poisons Centre 0344 892 0111
<p>Action if patient declines</p>	<ul style="list-style-type: none"> ▪ refer to authorised prescriber or doctor ▪ document in maternity record
<p>Additional advice and information</p>	<ul style="list-style-type: none"> ▪ observe for signs of candida infection in the genital area ▪ observe mother's nipples for signs of cross infection ▪ advise to contact midwife/GP if condition worsens or symptoms persist ▪ give the manufacturer's patient information leaflet to the woman
<p>Patient monitoring arrangements during and after treatment and follow-up required</p>	<p>Monitor response to treatment.</p> <p>Refer to doctor if no improvement after 5 days or sooner if symptoms worsen.</p>
<p>Particular storage requirements</p>	<p>-</p>
<p>References</p> <ol style="list-style-type: none"> 1. Summary of Product Characteristics Nystatin oral suspension (Sandoz). Text revision 7.3.2017. accessed 30.12.2019 http://www.medicines.org.uk 2. http://www.bnf.org 	